Table 4.
Treatments implemented between DLK stages.
| Stage I | Stage II | Stage III | Stage IV | |
|---|---|---|---|---|
| n (%) | n (%) | n (%) | n (%) | |
| Steroids | ||||
| Prednisolone, topical * | 530 (99.4) | 75 (98.7) | 22 (88.0) | 3 (100) |
| Difluprednate (Durezol *), topical *** | 80 (15.0) | 50 (65.8) | 17 (33.3) | 1 (33.3) |
| Dexamethasone, topical * | 0 (0) | 2 (2.6) | 2 (8.0) | 0 (0) |
| Methylprednisolone, oral *** | 8 (1.5) | 11 (14.5) | 13 (52.0) | 2 (66.7) |
| Antibiotic-Steroid Combinations | ||||
| Tobramycin/Dexamethasone, topical | 4 (0.8) | 0 (0) | 1 (4.0) | 0 (0) |
| Tobramycin/Loteprednol etabonate (Zylet *), topical | 1 (0.2) | 0 (0) | 0 (0) | 0 (0) |
| Antibiotics | ||||
| Ofloxacin, topical * | 419 (78.6) | 64 (84.2) | 17 (68) | 0 (0) |
| Moxifloxacin, topical | 137 (25.7) | 17 (22.4) | 10 (40.0) | 1 (33.3) |
| Polytrim, topical * | 0 (0) | 2 (2.6) | 0 (0) | 0 (0) |
| Azithromycin, topical | 2 (0.4) | 0 (0) | 0 (0) | 0 (0) |
| Doxycylcine, oral *** | 23 (4.3) | 9 (11.8) | 2 (8.0) | 2 (66.7) |
| Supplements | ||||
| Vitamin C *** | 0 (0) | 4 (5.3) | 4 (16.0) | 2 (66.7) |
| Coenzyme Q10 *** | 0 (0) | 1 (1.3) | 4 (16.0) | 0 (0) |
| Multivitamin* | 0 (0) | 0 (0) | 1 (4.0) | 0 (0) |
| Ocular Surface Treatments and Protection | ||||
| Bandage Contact Lens *** | 5 (0.9) | 7 (9.2) | 4 (16.0) | 0 (0) |
| Shield * | 0 (0) | 2 (2.6) | 0 (0) | 0 (0) |
| Gel tears *** | 15 (2.8) | 10 (13.2) | 4 (16.0) | 0 (0) |
| Muro-128 ointment | 0 (0) | 1 (1.3) | 0 (0) | 0 (0) |
| Punctal Plugs | 2 (0.4) | 0 (0) | 0 (0) | 0 (0) |
| Irrigation *** | 8 (1.5) | 11 (14.5) | 20 (80.0) | 1 (33.3) |
DLK—diffuse lamellar keratitis; *—p value ≤ 0.05; ***—p value ≤ 0.001. Bolded items indicate the general type of treatment used with specific treatments listed below.